Beilin_2005_Acta.Anaesthesiol.Scand_49_78

Reference

Title : Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period - Beilin_2005_Acta.Anaesthesiol.Scand_49_78
Author(s) : Beilin B , Bessler H , Papismedov L , Weinstock M , Shavit Y
Ref : Acta Anaesthesiologica Scandinavica , 49 :78 , 2005
Abstract :

BACKGROUND: Recently, new drugs and techniques for the treatment of postoperative pain were introduced, with the goal of enhancing opiates' analgesia while minimizing their side-effects. Cholinergic agents play an antinociceptive role, but their clinical use is quite limited, due to side-effects. Physostigmine is a cholinesterase inhibitor, which crosses the blood-brain barrier and elevates brain acetylcholine level. Physostigmine can produce analgesia by itself, and enhance opiate analgesia; but these effects are of short duration following bolus administration.
METHODS: We compared pain intensity and morphine consumption in two postoperative treatment groups: One group received continuous physostigmine infusion combined with morphine-based patient-controlled analgesia (PCA), and the other received PCA alone. Cholinergic anti-inflammatory pathways have recently been described. We therefore also compared changes in proinflammatory cytokine production in the two pain management groups.
RESULTS: Continuous infusion of physostigmine combined with morphine-based PCA in the postoperative period significantly reduced opiate consumption, and enhanced the analgesic response. Patients in the physostigmine group also exhibited reduced ex-vivo production of the proinflammatory cytokine, IL-1beta. At the same time, physostigmine increased nausea and vomiting, mostly in the first 2 h of the postoperative period.
CONCLUSIONS: Physostigmine combined with morphine in the postoperative period reduced morphine consumption, enhanced analgesia, and attenuated production of the proinflammatory cytokine, IL-1beta. This latter finding may account for the decreased pain observed in this group; this cytokine is known to mediate basal pain sensitivity and induce hyperalgesia in inflammatory conditions. Taking into account the other potential beneficial effects of physostigmine, we suggest that a continuous infusion of physostigmine should be considered as a useful component in multimodal postoperative analgesia.

PubMedSearch : Beilin_2005_Acta.Anaesthesiol.Scand_49_78
PubMedID: 15675987

Related information

Citations formats

Beilin B, Bessler H, Papismedov L, Weinstock M, Shavit Y (2005)
Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period
Acta Anaesthesiologica Scandinavica 49 :78

Beilin B, Bessler H, Papismedov L, Weinstock M, Shavit Y (2005)
Acta Anaesthesiologica Scandinavica 49 :78